Observational studyHaemophilia : the official journal of the World Federation of Hemophilia
The Swiss Haemophilia Registry-Report From the First 8 Years.
Observational study in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionPatient registries capture disease related information and provide a valuable source for real-world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act. It includes patients with inherited bleeding disorders, namely haemophilia A and B, von Willebrand disease (VWD), other rare bleeding disorders, and platelet function disorders.
aimTo describe the bleeding disorder landscape in Switzerland.
methodsThe SHR is an observational, prospective, longitudinal, multi-centre national registry. Individual patient data is collected annually and includes patient demographics, comorbidities, bleeding events and treatment.
resultsBy 2023, 929 patients were included in the SHR, with 60% diagnosed with haemophilia A, 17% with haemophilia B, and 15% with VWD. The cohort was predominantly male (87%), and 75% were adults. Median follow-up was 5.8 years (IQR 3.35-7.22). The prevalence of target joints in 2023 was 2%, with no affected children. Annual inhibitor prevalence in haemophilia patients was 1-2%. The SHR illustrates clearly the transition of prophylaxis products from plasma-derived to extended half-life factor products, and non-factor products, mirroring the global treatment evolution, and trends in individualised and patient-centred haemophilia management.
conclusionThe SHR provides real-world evidence on haemophilia care in Switzerland and documents major improvements in treatment and patient outcomes over the past decade. Future expansion will be more inclusive of VWD, rare bleeding disorders, and specifically women with bleeding disorders. This will enhance the value of the SHR as a comprehensive national resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.